Group 1 - The Swiss Medicines Agency has approved Novartis' Riamet Baby, a new anti-malaria drug specifically designed for newborns weighing between 2 to 5 kilograms, marking a significant advancement in the global fight against malaria [1] - Riamet Baby can dissolve in breast milk and has a sweet cherry flavor, making it easier for newborns to consume [1] - Prior to the approval of Riamet Baby, there were no approved treatments for malaria in newborns weighing less than 4.5 kilograms, which posed risks of overdose and increased toxicity when using formulations intended for older children [1] Group 2 - The approval process involved close collaboration with drug regulatory agencies from eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania [1] - The World Health Organization's Global Malaria Program participated in the scientific evaluation of Riamet Baby [1] - According to the WHO's 2024 World Malaria Report, 94% of malaria cases and 95% of malaria deaths in 2023 occurred in the African region, with 76% of deaths being children under five years old [2]